Denigration: The French Supreme Court rejects the entire appeal in the case of the delay in the entry of Durogesic generics on the market and thus confirms the 21 million euros penalty imposed on the laboratory and its parent company (Janssen-Cilag, Johnson & Johnson)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. By judgment adopted on June 1, 202221 million imposed by the Paris Court of Appeal in its judgment of July 11, 2019, in the case of the delay in the entry of Durogesic into the market, the Commercial Chamber of the Court of Cassation, rejecting in its entirety the appeal lodged by the laboratory Janssen-Cilag and its parent Johnson & Johnson. 21 million imposed on them by the Paris Court of Appeal in the case of the delay in the entry of generics of Durogesic. We recall that by decision n° 17-D-25 issued on December 20, 2017 25 million against the laboratory Janssen-Cilag, as the perpetrator, and its parent company Johnson & Johnson - imputability

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • L’actu-concurrence (Paris)

Quotation

Alain Ronzano, Denigration: The French Supreme Court rejects the entire appeal in the case of the delay in the entry of Durogesic generics on the market and thus confirms the 21 million euros penalty imposed on the laboratory and its parent company (Janssen-Cilag, Johnson & Johnson), 1 June 2022, Concurrences N° 3-2022, Art. N° 106986, www.concurrences.com

Visites 264

All reviews